Ranbaxy Patent application

Pub. No.:  WO/2008/099368  International Application No.:  PCT/IB2008/050568
Publication Date:21.08.2008International Filing Date:15.02.2008
IPC:
C07H 17/08 (2006.01), A61K 31/7028 (2006.01), A61P 31/04 (2006.01)
Applicants:RANBAXY LABORATORIES LIMITED [IN/IN]; Plot No. 90, Sector - 32, Gurgaon, Haryana 122001 (IN) (For All Designated States Except US).
CHAKRABARTI, Anjan [IN/IN]; (IN) (For US Only).
SURASE, Yogesh, Baban [IN/IN]; (IN) (For US Only).
KAKADE, Balasaheb [IN/IN]; (IN) (For US Only).
DAS, Biswajit [IN/IN]; (IN) (For US Only).
UPADHYAY, Dilip J. [IN/IN]; (IN) (For US Only)
Inventors:CHAKRABARTI, Anjan; (IN).
SURASE, Yogesh, Baban; (IN).
KAKADE, Balasaheb; (IN).
DAS, Biswajit; (IN).
UPADHYAY, Dilip J.; (IN)
Common
Representative:
RANBAXY LABORATORIES LIMITED; c/o George E. Heibel, 600 College Road East, Suite 2100, Princeton, NJ 08540 (US)
Priority Data:
319/DEL/2007 15.02.2007 IN
Title(EN) MACROLIDE DERIVATIVES AS ANTIBACTERIAL AGENTS
(FR) DÉRIVÉS DE MACROLIDES UTILISÉS COMME AGENTS ANTIBACTÉRIENS
Abstract:front page image
(EN)The present invention provides macrolide derivatives, which can be used as antibacterial agents. Compounds disclosed herein can be used for treating or preventing conditions caused by or contributed to by gram positive, gram negative or anaerobic bacteria, more particularly against, for example, Staphylococci, Streptococci, Enterococci, Haemophilus, Moraxella spp., Chlamydia spp., Mycoplasm, Legionella spp., Mycobacterium, Helicobacter, Clostridium, Bacteroides, Corynebacterium, Bacillus, Enterobactericeae or any combination thereof. Also provided, are processes for preparing compounds disclosed herein, pharmaceutical compositions containing compounds disclosed herein, and methods of treating bacterial infections.
(FR)La présente invention concerne des dérivés de macrolides pouvant être utilisés comme agents antibactériens. Les composés de l'invention peuvent être utilisés pour traiter ou prévenir des affections causées ou induites par des bactéries Gram positives, Gram négatives ou anaérobies, et agissent notamment contre Staphylococcus, Streptococcus, Enterococcus, Haemophilus, Moraxella spp., Chlamydia spp., Mycoplasm, Legionella spp., Mycobacterium, Helicobacter, Clostridium,Bacteroides, Corynebacterium, Bacillus, Enterobactericeae ou une combinaison quelconque de celles-ci. L'invention concerne également des procédés de préparation des composés susmentionnés, des compositions pharmaceutiques renfermant ces composés et des méthodes de traitement d'infections bactériennes.

Comments

Popular posts from this blog

Pantoprazole EP Impurity B Manufacturer and Supplier

Pantoprazole EP Impurity C Manufacturer and Supplier

Cetirizine EP Impurity G Manufacturer and Supplier